Natdecita — Decitabine for Injection 50 mg, 1 Vial

Natdecita is supplied in the form of a lyophilized powder for solution for infusion.

Qualitative and Quantitative Composition per Vial:

• Active Ingredient: Decitabine — 50 mg.
• Excipients: Potassium dihydrogen phosphate, sodium hydroxide and/or hydrochloric acid (for pH adjustment).

Packaging and Presentation: White to off-white lyophilized powder or cake. Supplied in a single-use clear glass vial containing 50 mg decitabine, sealed with a rubber stopper and an aluminum flip-off cap. Each vial is packaged in an outer carton displaying Natdecita (Decitabine Lyophilized for Injection) 50 mg along with Natco Pharma corporate graphics.

Pharmacodynamics:
Decitabine is a deoxycytidine analogue. Its mechanism of action is dual: at lower doses, it induces DNA hypomethylation via DNMT inactivation, re-activating tumor suppressor genes and cellular differentiation pathways. At higher doses, direct cytotoxicity predominates via DNA integration and synthesis inhibition, precipitating cell death.

Pharmacokinetics:

• Distribution: Following IV infusion, decitabine rapidly distributes throughout body tissues and fluids. Features a wide distribution volume. Plasma protein binding is minimal (< 1%).
• Metabolism: Rapidly metabolized in the liver, granulocytes, and other peripheral tissues by cytidine deaminase via deamination into an inactive metabolite.
• Elimination: Features a very short elimination half-life (~35–47 minutes). Excreted primarily via the kidneys as inactive metabolites.

Natdecita is indicated in adult patients for:

• Myelodysplastic Syndromes (MDS): Treatment of patients with all MDS subtypes (including refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia).
• Acute Myeloid Leukemia (AML): Treatment of newly diagnosed primary or secondary AML in adult patients (aged 65 years and older) who are not candidates for standard intensive induction chemotherapy.

Natdecita is administered strictly via intravenous infusion under expert hematologist supervision.

Reconstitution and Dilution Instructions:

• Reconstitution: Reconstitute the 50 mg vial aseptically with 10 ml of Sterile Water for Injection (yielding a 5 mg/ml concentration).
• Dilution: Immediately dilute the reconstituted solution in 0.9% Sodium Chloride or 5% Dextrose injection to a final concentration of 0.1 to 1.0 mg/ml.

Dosing Regimen:

• 3-Day Regimen: 15 mg/m2 body surface area IV over 3 hours every 8 hours (3 times daily) for 3 consecutive days every 6 weeks.
• 5-Day Regimen: 20 mg/m2 body surface area IV over 1 hour once daily for 5 consecutive days every 4 weeks.

Administration of Natdecita is contraindicated in:

• Hypersensitivity: Known hypersensitivity to decitabine or any inactive excipient.
• Severe Hepatic or Renal Impairment: Severe functional impairment of liver or kidney function.
• Pregnancy and Lactation: Contraindicated in pregnant or nursing women.
• Pediatric Population: Safety and efficacy in individuals under 18 years of age have not been established.

Evaluated drug interactions for Natdecita include:

• Myelosuppressive Agents: Co-administration with other chemotherapy or myelosuppressive agents compounds bone marrow suppression risks.
• Cytidine Deaminase Substrates: Competitive metabolism via cytidine deaminase may alter pharmacokinetics when co-administered with nucleoside analogues (e.g., gemcitabine, cytarabine).

Pregnancy:
Natdecita is strictly contraindicated during pregnancy due to potent embryotoxic, mutagenic, and teratogenic risks. Male and female patients must use effective contraception during therapy and for at least 3–6 months post-treatment.

Lactation:
Breastfeeding is strictly prohibited during decitabine therapy.

The most frequent and clinically relevant adverse reactions reported with decitabine include:

• Hematologic Toxicity (Very Common): Severe neutropenia, thrombocytopenia, anemia, febrile neutropenia, hemorrhagic events.
• Infections: Pneumonia, sepsis, fungal and bacterial infections.
• Gastrointestinal Tract: Nausea, vomiting, diarrhea, constipation, stomatitis, abdominal pain.
• General & Nervous System: Pyrexia, fatigue, headache, insomnia, peripheral edema.
• Laboratory Changes: Hyperbilirubinemia, transient hepatic transaminase elevations.

Symptoms:
Decitabine overdose manifests as profound bone marrow suppression (prolonged neutropenia and thrombocytopenia), severe infectious complications, and mucositis.

Treatment:
No specific antidote exists. Supportive and symptomatic care should be initiated: blood product transfusions, granulocyte colony-stimulating factors (G-CSF), broad-spectrum antimicrobial cover, and vital sign monitoring.

Storage Requirements for Natdecita:

• 🌡️ Temperature Control: Store in a dry, light-protected place at temperatures not exceeding 25 °C (77 °F).
• ☀️ Light Protection: Keep vial in the outer carton to protect from light.
• 💧 Reconstituted Solution: Infusion solutions should be administered immediately after preparation. Diluted solutions prepared with cold fluids may be stored at 2–8 °C (36–46 °F) for up to 7 hours before infusion.
• 👶 Safety Precautions: Keep strictly out of reach of children.
• ⏳ Shelf Life: Stated on vial label and box. Do not use past expiration date. Prescription-only medicine for hospital use.

To verify the authenticity of original Natdecita produced by Natco Pharma, check the following details:

• ✅ Corporate Logo: Distinctive blue-green Natco Pharma logo printed on the outer box and vial label.
• ✅ Packaging Details: Clear factory printing displaying Batch No., Mfg. Date, Exp. Date, and product designation Natdecita (Decitabine Lyophilized for Injection) 50 mg.
• ✅ Vial Cap Seal: Intact plastic flip-off seal over aluminum crimp ring.
• ✅ Print Quality: High-grade packaging artwork with precise typography and a securely sealed vial.